Feed Antibiotics Market

Executive Summary

Feed Antibiotics Market was valued at US $43.43 billion in 2021 and is projected to grow at 4.55% CAGR over the forecast period to reach US $56.72 billion by 2027. Feed Antibiotics Market represented US $3.70 billion opportunity over 2019-2021 and estimated to create US $13.29 billion opportunity in 2027 over 2021.

Feed Antibiotics from Consainsights analyses the Feed Antibiotics Market in the Life Sciences industry over the forecast period to 2027.

Feed Antibiotics research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Feed Antibiotics segmentation includes Type, Animal Type and Geography.

Based on the Type, the Feed Antibiotics analysis covers Tetracyclines, Penicillins, Sulfonamides, Macrolides, Aminoglycosides, Cephalosporins, Others.

In Type segment, Tetracyclines segment has highest cagr growth of 4.03%.

Based on the Animal Type, the Feed Antibiotics analysis covers Ruminant, Poultry, Swine, Aquaculture, Others.

In Animal Type segment, Ruminant segment has highest cagr growth of 4.03%.

Based on the region, the Feed Antibiotics analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Bayer HealthCare AG, Merck Animal Health, Zomedica, Elanco, Sanofi-Aventis SA, LG Life Sciences Limited, American Regent Inc., ECO Animal Health, Zoetis, Alpha-Vet Animal Health and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Type

Introduction

In 2021, Tetracyclines segment has the highest revenue of US $16.94 billion and is expected to grow at CAGR of 4.03% by 2027 Tetracyclines segment has highest cagr growth of 4.03%.

Tetracyclines

Tetracyclines segment was valued at US $15.50 billion in 2019 and is projected to grow at 4.03% CAGR over the forecast period to reach US $22.13 billion by 2027. Tetracyclines segment represented US $1.44 billion opportunity over 2019-2021 and estimated to create US $5.18 billion opportunity in 2027 over 2021.

Penicillins

Penicillins segment was valued at US $10.04 billion in 2019 and is projected to grow at 4.03% CAGR over the forecast period to reach US $14.34 billion by 2027. Penicillins segment represented US $0.93 billion opportunity over 2019-2021 and estimated to create US $3.36 billion opportunity in 2027 over 2021.

Sulfonamides

Sulfonamides segment was valued at US $5.30 billion in 2019 and is projected to grow at 4.03% CAGR over the forecast period to reach US $7.57 billion by 2027. Sulfonamides segment represented US $0.49 billion opportunity over 2019-2021 and estimated to create US $1.77 billion opportunity in 2027 over 2021.

Macrolides

Macrolides segment was valued at US $4.15 billion in 2019 and is projected to grow at 4.03% CAGR over the forecast period to reach US $5.92 billion by 2027. Macrolides segment represented US $0.39 billion opportunity over 2019-2021 and estimated to create US $1.39 billion opportunity in 2027 over 2021.

Aminoglycosides

Aminoglycosides segment was valued at US $2.35 billion in 2019 and is projected to grow at 4.03% CAGR over the forecast period to reach US $3.36 billion by 2027. Aminoglycosides segment represented US $0.22 billion opportunity over 2019-2021 and estimated to create US $0.79 billion opportunity in 2027 over 2021.

Cephalosporins

Cephalosporins segment was valued at US $2.12 billion in 2019 and is projected to grow at 4.03% CAGR over the forecast period to reach US $3.02 billion by 2027. Cephalosporins segment represented US $0.20 billion opportunity over 2019-2021 and estimated to create US $0.71 billion opportunity in 2027 over 2021.

Others

Others segment was valued at US $0.26 billion in 2019 and is projected to grow at 4.03% CAGR over the forecast period to reach US $0.38 billion by 2027. Others segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.09 billion opportunity in 2027 over 2021.

Animal Type

Introduction

In 2021, Ruminant segment has the highest revenue of US $18.55 billion and is expected to grow at CAGR of 4.03% by 2027 Ruminant segment has highest cagr growth of 4.03%.

Ruminant

Ruminant segment was valued at US $16.97 billion in 2019 and is projected to grow at 4.03% CAGR over the forecast period to reach US $24.22 billion by 2027. Ruminant segment represented US $1.58 billion opportunity over 2019-2021 and estimated to create US $5.68 billion opportunity in 2027 over 2021.

Poultry

Poultry segment was valued at US $11.08 billion in 2019 and is projected to grow at 4.03% CAGR over the forecast period to reach US $15.82 billion by 2027. Poultry segment represented US $1.03 billion opportunity over 2019-2021 and estimated to create US $3.71 billion opportunity in 2027 over 2021.

Swine

Swine segment was valued at US $4.96 billion in 2019 and is projected to grow at 4.03% CAGR over the forecast period to reach US $7.08 billion by 2027. Swine segment represented US $0.46 billion opportunity over 2019-2021 and estimated to create US $1.66 billion opportunity in 2027 over 2021.

Aquaculture

Aquaculture segment was valued at US $2.49 billion in 2019 and is projected to grow at 4.03% CAGR over the forecast period to reach US $3.55 billion by 2027. Aquaculture segment represented US $0.23 billion opportunity over 2019-2021 and estimated to create US $0.83 billion opportunity in 2027 over 2021.

Others

Others segment was valued at US $4.23 billion in 2019 and is projected to grow at 4.03% CAGR over the forecast period to reach US $6.04 billion by 2027. Others segment represented US $0.39 billion opportunity over 2019-2021 and estimated to create US $1.42 billion opportunity in 2027 over 2021.